TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28891367

Group type: EXPERIMENTAL
Intervention: Foeniculum vulgare (fennel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27746539

Group type: EXPERIMENTAL
Intervention: 3 mg intrathecal levobupivacaine with 25 μg fentanyl followed by epidural top‐ups of 14 ml of levobupivacaine 0.125% with fentanyl 30 μg
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4 mg intrathecal ropivacaine with 25 μg fentanyl followed by epidural top‐ups of 14 ml of ropivacaine 0.2% with fentanyl 30 μg
Number of subjects: 60
Study: 24048718

Group type: EXPERIMENTAL
Intervention: IV fluid guided by stroke volume (SV)
Number of subjects: 135

Group type: COMPARATOR
Intervention: IV fluid guided by central venous pressure (CVP)
Number of subjects: 135
Study: 23908479

Group type: EXPERIMENTAL
Intervention: Heat-treated zoster vaccine (ZVHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20181456

Group type: EXPERIMENTAL
Intervention: Well-Being Therapy (WBT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Anxiety Management (AM)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Psychological Well-Being Scales (PWB)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire (SQ)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Revised Children's Manifest Anxiety Scale (RCMAS)
Number of subjects: 162
Study: 18208424

Group type: EXPERIMENTAL
Intervention: The '11' exercise program (15-min program consisting of ten exercises for core stability, lower extremity strength, balance and agility)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 17002045

Group type: EXPERIMENTAL
Intervention: Adjuvant SUMS‐1 (n = 38)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Adjuvant enterosgel (n = 37)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 110
Study: 12779268

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DF) and Deferiprone (L1)
Number of subjects: 72
Study: 10950766

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Saquinavir soft-gel capsules (SQVsgc)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Saquinavir hard capsules (SQVhc)
Number of subjects: 89
Study: 8979093

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: No antihypertensive therapy
Number of subjects: 25
Study: 1468245

Group type: EXPERIMENTAL
Intervention: 20 mg sodium hyaluronate in 2 ml phosphate buffer for 5 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 mg sodium hyaluronate in 2 ml phosphate buffer for 5 weeks + 0.4 mg dexamethasone phosphate
Number of subjects: 40
Study: 373254

Group type: EXPERIMENTAL
Intervention: Tagamet (cimetidine) 1 g daily (3x200 mg after meal and 400 mg in the evening) for 20 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tagamet (cimetidine)
Number of subjects: 25
Study: 31619065

Group type: EXPERIMENTAL
Intervention: Delayed hard palate closure (at age 36 months)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Early hard palate closure (at age 12 months)
Number of subjects: 122
Study: 31727085

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise programme
Number of subjects: 64

Group type: COMPARATOR
Intervention: General exercise programme
Number of subjects: 64
Study: 27834670

Group type: EXPERIMENTAL
Intervention: Resistance training with instability (RTI)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 37
Study: 26501125

Group type: EXPERIMENTAL
Intervention: Telephone consultation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 86
Study: 23932494

Group type: EXPERIMENTAL
Intervention: ESR2 polymorphisms (specifically A allele of rs1256049)
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: ESR2 polymorphisms (specifically A allele of rs4986938)
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: ESR1 polymorphisms (rs2234693 and rs9340799)
Number of subjects: 3799
Study: 22143987

Group type: EXPERIMENTAL
Intervention: High negative Lindenmayer scores
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Medium negative Lindenmayer scores
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low negative Lindenmayer scores
Number of subjects: 126
Study: 19839254

Group type: EXPERIMENTAL
Intervention: Group I (n = 74) underwent septoplasty with transseptal suturing, and conchotomy with glue as a haemostatic.
Number of subjects: 146

Group type: COMPARATOR
Intervention: Group II (n = 72) underwent septoplasty and conchotomy with glue as a haemostatic as well as septal cartilage and mucoperichodrial flaps sealant (no transseptal suturing).
Number of subjects: 146
Study: 17080754

Group type: EXPERIMENTAL
Intervention: Proportional hazards (PH) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated failure time (AFT) model
Number of subjects: 0
Study: 15633195

Group type: EXPERIMENTAL
Intervention: BRCA1/2 testing (n = 181, 85%)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Client-centered counseling intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Non-testers (those who declined testing)
Number of subjects: 212
Study: 12784116

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study: 10441812

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 737

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 737
Study: 7877646

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, and fluorouracil) for 12 monthly cycles
Number of subjects: 386

Group type: COMPARATOR
Intervention: No further treatment after radical mastectomy
Number of subjects: 386
Study: 2172161

Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg once or 5 mg four times at 6-hour intervals)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: In vitro assays using Z-Phe-His-Leu as substrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Plasma angiotensin II
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Plasma angiotensin II to angiotensin I ratio
Number of subjects: 9
Study: 398480

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 55

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 55
Study: 29092038

Group type: COMPARATOR
Intervention: PVAC ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: nMARQ ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Catheter ablation (PVAC and nMARQ combined)
Number of subjects: 0
Study: 28578163

Group type: EXPERIMENTAL
Intervention: SAC urinary catheter (experimental group)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Standard catheter (control group)
Number of subjects: 489
Study: 24554463

Group type: EXPERIMENTAL
Intervention: DQ‐MA imaging with τ = 3 ms
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: DQ‐MA imaging with 1 or 2 averages
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Higher nominal resolution DQ‐MA imaging
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: DQ‐MA sequence
Number of subjects: 5
Study: 23818692

Group type: EXPERIMENTAL
Intervention: 1.36 g L-carnitine + 80 g carbohydrate (Carnitine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80 g carbohydrate (Control)
Number of subjects: 12
Study: 21437714

Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 133

Group type: COMPARATOR
Intervention: almotriptan 12.5 mg
Number of subjects: 133
Study: 18822917

Group type: EXPERIMENTAL
Intervention: Sodium ferulate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional liver protecting therapy (Control)
Number of subjects: 82
Study: 15899709

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 1
Study: 12950604

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (omeprazole 4 x 40 mg and amoxicillin 4 x 750 mg for 14 days)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole 2 x 20 mg, bismuthcitrate 4 x 107 mg, metronidazole 4 x 500 mg and tetracycline 4 x 500 mg for 14 days)
Number of subjects: 84
Study: 10370394

Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 22

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 22
Study: 8829931

Group type: EXPERIMENTAL
Intervention: Nasal inhalation of sevoflurane 5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral inhalation of sevoflurane 5%
Number of subjects: 20
Study: 2068468

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg) plus aztreonam (1 g)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Clindamycin (600 mg) plus gentamicin (80 mg)
Number of subjects: 138
Study: 7048482

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 31286694

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 2, 4, and 6 L/min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bubble CPAP
Number of subjects: 24
Study: 29214975

Group type: EXPERIMENTAL
Intervention: HomeHealth intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51

Group type: COMPARATOR
Intervention: NHS and carer support costs
Number of subjects: 51
Study: 26022434

Group type: EXPERIMENTAL
Intervention: RCA plus low-dose dalteparin
Number of subjects: 53

Group type: COMPARATOR
Intervention: RCA only
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal-dose dalteparin
Number of subjects: 53

Group type: COMPARATOR
Intervention: RCA only, Normal-dose dalteparin
Number of subjects: 53
Study: 24424707

Group type: EXPERIMENTAL
Intervention: Vortioxetine 2.5 mg
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 22498720

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Telemonitoring and Case Management (TI)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 450
Study: 19528889

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (30 periods)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study: 17478880

Group type: EXPERIMENTAL
Intervention: Topically applied heparin spraygel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (peroral analgesics or nonsteroidal anti‐inflammatory drugs, elastic stockings, mild ambulation)
Number of subjects: 0
Study: 15111231

Group type: EXPERIMENTAL
Intervention: Symmetrical stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetrical stimuli
Number of subjects: 0
Study: 12815777

Group type: EXPERIMENTAL
Intervention: Mivacron (0.15 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacron (0.1 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suxamethonium chloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacron
Number of subjects: 20
Study: 9274466

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g four times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: sucralfate 2 g twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 8391041

Group type: EXPERIMENTAL
Intervention: 1 MU interferon 3 times a week for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 MU interferon 3 times a week for 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-therapy liver biopsy
Number of subjects: 30
Study: 3551432

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 20
Study: 31317285

Group type: EXPERIMENTAL
Intervention: Real-time EEG feedback on occipital alpha lateralization
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham feedback
Number of subjects: 14
Study: 29986040

Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27503849

Group type: EXPERIMENTAL
Intervention: Change in heart rate from supine to upright position (∆HR)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Change in heart rate from baseline to month 6
Number of subjects: 321
Study: 24262498

Group type: EXPERIMENTAL
Intervention: Polidocanol (1, 3, or 4 ml depending on hydrocele size) after aspiration
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 22313070

Group type: EXPERIMENTAL
Intervention: adrenaline 1:400,000 (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: adrenaline 1:200,000 (group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: lignocaine + adrenaline 1:400,000 (group C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: lignocaine + adrenaline 1:200,000 (group D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: lignocaine added to infiltrating solution
Number of subjects: 100
Study: 20089522

Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/day, orally)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Leuprolide acetate (3.75 mg, depot i.m. injection, every 4 weeks)
Number of subjects: 252
Study: 18453852

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir tablets (600/150 mg or 800/200 mg twice daily) with 600 mg rifampicin once daily
Number of subjects: 40
Study: 15753741

Group type: EXPERIMENTAL
Intervention: 4 ng/kg intravenous Escherichia coli endotoxin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline day with no intervention
Number of subjects: 8
Study: 14740279

Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 33

Group type: COMPARATOR
Intervention: Humulin 30/70
Number of subjects: 33
Study: 10423312

Group type: EXPERIMENTAL
Intervention: salbutamol 200 microg (S)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: fenoterol 200 microg (F)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: salbutamol 200 microg + beclomethasone 100 microg (S + B)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: fenoterol 200 microg + ipratropium bromide 80 microg (F + IB)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg (SM)
Number of subjects: 214

Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 214
Study: 7673657

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 2301851

Group type: EXPERIMENTAL
Intervention: Inspiratory capacity (IC) with breathholding aided by a one‐way valve
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Uncoached breath‐stacking (valved) maneuvers
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard inspiratory capacity without valve or inspiratory hold
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Initial coached IC effort with subsequent valved stacking of tidal efforts
Number of subjects: 26
Study: 7437237

Group type: EXPERIMENTAL
Intervention: Indoramin 75 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 0
Study: 31200665

Group type: EXPERIMENTAL
Intervention: Antenatal only trajectory (91.4%)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Antenatal and postnatal trajectory (8.6%)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Predictors for antenatal and postnatal trajectory
Number of subjects: 384
Study: 29843507

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (Group I)
Number of subjects: 80
Study: 26651347

Group type: EXPERIMENTAL
Intervention: CLI (command line interface) with keyboard shortcuts
Number of subjects: 2

Group type: COMPARATOR
Intervention: GUI (graphical user interface) using dropdown menu
Number of subjects: 2
Study: 25354950

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High intensity interval training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 22504154

Group type: EXPERIMENTAL
Intervention: Weight‐bearing (WB) exercises
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Seated resistance (SR) exercises
Number of subjects: 180

Group type: COMPARATOR
Intervention: Social visits (C)
Number of subjects: 180
Study: 20067667

Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex diaphragm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: FemCap cervical cap
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cervical barriers (CB) overall
Number of subjects: 45
Study: 19089746

Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 25% 1 RM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 30% 1 RM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 35% 1 RM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 40% 1 RM
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isometric submaximal contraction at 50% MVC (reference contraction)
Number of subjects: 10
Study: 16237763

Group type: EXPERIMENTAL
Intervention: Helico Blot 2.1
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CagA antigen and Helico Blot 2.1
Number of subjects: 33
Study: 12165596

Group type: EXPERIMENTAL
Intervention: Oral 30% glucose (0.3 mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.3 mL of sterile water)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral 30% glucose (0.3 mL) plus pacifier
Number of subjects: 40
Study: 10208545

Group type: EXPERIMENTAL
Intervention: Magnetoencephalographic (MEG) signals measured from the left frontal area
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onset of MEG response
Number of subjects: 0
Study: 7870752

Group type: EXPERIMENTAL
Intervention: Oscillatory posteroanterior mobilizations under different conditions of stiffness
Number of subjects: 10
Study: 2221645

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 375679

Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 60
Study: 6760120

Group type: EXPERIMENTAL
Intervention: Porcine extracted monocomponent insulins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human semi‐synthetic insulins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both types of insulin therapy
Number of subjects: 0
Study: 31701593

Group type: EXPERIMENTAL
Intervention: Minimally interrupted direct oral anticoagulation (DOAC) therapy
Number of subjects: 584

Group type: COMPARATOR
Intervention: Uninterrupted direct oral anticoagulation (DOAC) therapy
Number of subjects: 584
Study: 29177507

Group type: EXPERIMENTAL
Intervention: Lobe-specific nodal dissection
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Systematic nodal dissection
Number of subjects: 1700
Study: 27317706

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg s.c. injection)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study: 24338120

Group type: EXPERIMENTAL
Intervention: Umbilical cord serum IL‐6 above the 75th percentile
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Umbilical cord serum CRP above the 75th percentile
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Umbilical cord serum IL‐6, CRP, or MPO above the 75th percentile
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Umbilical cord serum IL‐6, CRP, or MPO
Number of subjects: 400
Study: 22709272

Group type: EXPERIMENTAL
Intervention: 5% nicotinamide lotion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 500 mg oral nicotinamide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 20610752

Group type: EXPERIMENTAL
Intervention: Electroencephalographic responses linked with perceptual priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different potentials recorded during initial presentations
Number of subjects: 0
Study: 18274646

Group type: EXPERIMENTAL
Intervention: Amino acids plus glucose (AAG) dialysate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose alone (control)
Number of subjects: 6
Study: 15732070

Group type: EXPERIMENTAL
Intervention: Fluoxetine with guided self-help
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoxetine without guided self-help
Number of subjects: 50
Study: 14609009

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10544229

Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7594660

Group type: EXPERIMENTAL
Intervention: Ro 24-7429 (Tat antagonist) at 75, 150, or 300 mg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nucleoside analogue (zidovudine or didanosine)
Number of subjects: 96
Study: 2087280

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 40
Study: 314399

Group type: EXPERIMENTAL
Intervention: Enelbin‐Rheuma‐ointment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reference ointment
Number of subjects: 100
Study: 30169322

Group type: EXPERIMENTAL
Intervention: Low-exposure everolimus (3-7 ng/mL)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High-exposure everolimus (9-15 ng/mL)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Everolimus (3-15 ng/mL) during extension phase
Number of subjects: 299